Corbus Pharma Chief Business Officer buys 13,500 shares for $101,218.50 across two June transactions
Nishant C Saxena purchased 13,500 shares in two separate transactions at an average price of $7.50, a modest premium to the current price of $7.38. The stock is down 64.1% from its 52-week high of $20.56 and down 29.8% over the past 30 days. The company generated $0.00 in revenue in its latest quarter, reported a net loss of $-22,969,000.00 for the full year, and experienced -100.0% annual revenue growth, indicating a company in financial distress with no active commercial operations. While the insider's holdings increased by 21.8%, the timing follows a steep recent decline and comes amid fundamental deterioration, making the significance of this purchase unclear without visibility into whether this represents routine capital allocation or a targeted response to distressed conditions.